Repositioning Candidate Details
| Candidate ID: | R0204 |
| Source ID: | DB00709 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Lamivudine |
| Synonyms: | |
| Molecular Formula: | C8H11N3O3S |
| SMILES: | NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1 |
| Structure: |
|
| DrugBank Description: | A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). |
| CAS Number: | 134678-17-4 |
| Molecular Weight: | 229.256 |
| DrugBank Indication: | For the treatment of HIV infection and chronic hepatitis B (HBV). |
| DrugBank Pharmacology: | Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV) to disrupt viral DNA synthesis. When phosphorylated, lamivudine can form active metabolites that compete for incorporation into viral DNA. Via DNA incorporation, lamivudine metabolites competitively inhibit the activity of the HIV reverse transcriptase enzyme and act as a chain terminator of DNA synthesis. Due to the lack of a 3'-OH group, incorporated nucleoside analogues prevent the formation of a 5' to 3' phosphodiester linkage that is essential for DNA chain elongation. |
| DrugBank MoA: | Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination. |
| Targets: | Reverse transcriptase/RNaseH; DNA; Protein P |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |